Corcept Therapeutics reported robust Q2 2026 results with $256.1 million in revenue, a 32% increase year-over-year, driven by a $47.6 million launch of its oncology drug Lifyorli. The company is evolving from a single-focus endocrine treatment to a multi-engine growth platform, supported by new studies showing Cushing's disease is more common than previously thought, which expands the market potential significantly. Despite higher launch expenses, Corcept maintained profitability and shows promising pipeline options and durable fundamentals, leading to a positive outlook for the second half of 2026.
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...
EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...
Lakeland Industries continues to face profitability challenges with a projected negative EPS of -$0.06 and recent unprofitability. However, the company secured important contracts with the Hong Kong Government Flying Service and Airports of Thailand,...
Binance founder Changpeng Zhao (CZ) predicts that bitcoin could overtake gold in market value as soon as the next bull market, citing the narrowing valuation gap currently around 10 times. He highlights that bitcoin's growing correlation with gold, n...
Unusual Machines stock surged 100% in one month to $25.51, significantly outperforming other drone companies like Red Cat Holdings and Ondas, which saw declines. The company's revenue jumped 687% year over year in Q2, driven by strong demand for dron...
